MultiOmic discovers and develops life-changing precision medicines for metabolic syndrome-derived diseases. Metabolic syndrome refers to a set of lifestyle and age-related risk factors — dysglycemia, hypertension, dyslipidemia, obesity — that lead to multiple (and often concurrent) serious medical conditions such as atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver. This group of closely-related conditions constitutes the world’s costliest healthcare burden, consuming $2 trillion in global healthcare costs in 2019 (1.6 times more than cancer), a cost that is forecast to exceed $5.5 trillion by 2040.

Using our unique combination of deep longitudinal patient datasets, AI-enabled data science capabilities and experimental biology expertise, we identify patient subpopulations having their own distinct molecular-level disease drivers. We use these insights to originate and pursue our own therapeutic R&D programmes, each with the corresponding patient-stratifying biomarkers. This precision medicine approach enables shorter and smaller clinical trials with inherently higher success rates.

MultiOmic commercialises its therapeutics programmes via licensing arrangements and partnerships with other biopharma companies. We also collaborate with diagnostic companies to implement our patient-stratifying biomarkers as companion diagnostics for our therapeutics.